Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential RNA programs
The agreement gives Novartis an exclusive worldwide license to ABO2203 and options on other RNA programs, with up to $7.2 billion in milestones.
- On Friday, October 2, 2026, Swiss pharmaceutical giant Novartis signed a licensing agreement with Chinese biotech Abogen Biosciences to develop mRNA-encoded therapies for autoimmune diseases, valued at up to $7.8 billion.
- The agreement centers on ABO2203, an experimental CD19xCD3 T-cell engager designed to treat B-cell-mediated autoimmune diseases, which uses mRNA to instruct patients' own cells to destroy disease-causing B-cells.
- Abogen Chief Executive Officer Bo Ying said the pact underscores the "broad potential of our RNA platform," while Novartis President of Biomedical Research Fiona Marshall added that mRNA-encoded T-cell engagers could "complement existing therapeutic modalities."
- Novartis stock slipped 0.5% during Friday's session, though Gillian Hollenstein, lead manager at Point Capital Navigator Fund, told Reuters the deal carries a "better risk profile" due to its front-loaded structure.
- Securing exclusive options for additional programs, Novartis also remains eligible to receive up to $7.2 billion in potential milestone payments if the therapy clears development and commercial hurdles.
30 Articles
30 Articles
Novartis has concluded an agreement valued at up to $7.8 billion to license a candidate for Chinese medicine from Abogen Biosciences and obtain options on future therapies, in the latest partnership between a large Western pharmaceutical company and an emerging Chinese company. Exclusive material for subscribers. To have full access, access the link of the subject and register.
Novartis strikes about $7.8 billion mRNA deal with China’s Abogen
Oct 2 (Reuters) - Chinese biotech company Abogen said on Friday it signed a licensing and option agreement worth about $7.8 billion with Swiss drug maker Novartis to advance RNA-based therapy. (Reporting by Ruchika Khanna in Bengalu...
InsideNoVA.com
Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential RNA programs
Includes worldwide license to ABO2203, Abogen's mRNA-encoded CD19xCD3 T-Cell Engager
Big Pharma’s China deal worth up to $7.8 billion – Ya Libnan
Novartis has signed a deal worth up to $7.8 billion, in the latest of a flurry of tie-ups between Big Pharma and Chinese biotechs. The Swiss pharma major is entering a licensing agreement with China-based Abogen Biosciences for its lead asset, an early-stage experimental treatment for autoimmune disease, Abogen said in a statement on Friday. China offers Western […]
Key takeaways: Large pharmaceutical companies are increasingly seeking collaboration with Chinese biotechnology companies to supplement their product pipelines, as patents on various revenue-generating drugs are about to expire. We see this trend reflected, among others, in a recent agreement between Novartis and Abogen Biosciences. The Swiss company is initially paying 575 […]
Coverage Details
Bias Distribution
- 63% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
